Fig. 2.

Summary of the interventions (a), and outcomes (b). The RAM + taxane intervention shown in a corresponds to RAM + PTX/nab-PTX as reported in the original studies. The original studies did not present individual results for RAM + PTX or RAM + nab-PTX. Similarly, the original study did not provide separate results on RAM or RAM + PTX in the intervention named RAM or RAM + PTX. AEs adverse events, DCR disease control rate, DoT duration of treatment, nab-PTX albumin-bound paclitaxel, ORR objective response rate, OS overall survival, PDT post-discontinuation treatment, PFS profession-free survival, PTX paclitaxel, RAM ramucirumab, RDI relative dose intensity, TD treatment discontinuation